Alzheimer disease
A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.
Read more about Alzheimer diseaseTrial-stage treatments and research studies you can joinOpen trials for referral
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Filters
- Tests KarXT with KarX-EC for memory and thinking problems in Alzheimer's disease
Tests KarXT with KarX-EC against a placebo in people with mild to moderate Alzheimer's.
Bordeaux, FranceAlso Bron, Marseille, Nancy, Paris, Saint-Herblain, Strasbourg, ToursAge 60 to 85 - Testing KarXT with KarX-EC for memory problems in Alzheimer's disease
Tests KarXT with KarX-EC against placebo in adults with mild to moderate Alzheimer's disease.
Dijon, FranceAlso Nice, ToulouseAge 60 to 85 - Tests RO7568282 against a placebo in early Alzheimer's disease
Compares RO7568282 with a placebo in people in early Alzheimer's disease.
Bron, FranceAlso Paris, ToulouseAge 50 to 90 - Long-Term Safety Study of KarXT for Psychosis in Alzheimer's Disease
Tests KarXT, a long-term safety study in people with Alzheimer's-related psychosis.
Toulouse, FranceAlso ToursAge 55 to 90 - Tests ML-007C-MA for hallucinations and delusions in Alzheimer's disease psychosis
Tests ML-007C-MA against placebo in people with Alzheimer's psychosis.
Strasbourg, FranceAge 55 to 90 - Long-term study of KarXT and KarX-EC for agitation in Alzheimer's disease
Tests KarXT and KarX-EC over time in people with Alzheimer's-related agitation.
Limoges, FranceAlso Paris, StrasbourgAge 55 to 90 - Long-term safety of ML-007C-MA for hallucinations and delusions in Alzheimer's disease
Tests ML-007C-MA over 52 weeks in adults with Alzheimer's disease psychosis.
Strasbourg, FranceAlso ToulouseAge 55 to 91 - Tests ACP-204 for psychosis in people with Alzheimer's disease
Tests ACP-204 against placebo in adults with Alzheimer's disease psychosis.
Dijon, FranceAlso Limoges, Paris, Rouen, Toulouse, ToursAge 55 to 95 - Long-term study of ACP-204 for psychosis linked to Alzheimer's disease
Checks the long-term safety of ACP-204 in older adults with Alzheimer's psychosis.
Dijon, FranceAlso Limoges, Paris, Rouen, Toulouse, ToursAge 55 to 95 - Tests KarXT with KarX-EC for agitation in Alzheimer's disease
Tests KarXT with KarX-EC against placebo in adults with Alzheimer's-related agitation.
Paris, FranceAge 55 to 90 - KarXT Tested for Psychosis in People With Alzheimer's Disease
Tests KarXT against placebo in adults with Alzheimer's and psychosis.
Nice, FranceAlso Toulouse, ToursAge 55 to 90 - Tests a light and magnetic device in people with early Alzheimer's disease
Tests the RGn600 light and magnetic device in people with early Alzheimer's.
Castres, FranceAlso Lavaur, Paris, Saint-Herblain, Toulouse, VilleurbanneAge 55 to 85 - Studies brain resilience in early-onset Alzheimer's and posterior cortical atrophy using PET and MRI
Uses PET and MRI brain scans to study patients with early Alzheimer's disease.
FranceAge 40 to 80 - Tests KarXT for psychosis linked to Alzheimer's disease
Tests KarXT against placebo in people with Alzheimer's-related psychosis to prevent relapse.
Dijon, FranceAlso Reims, Rouen, VilleurbanneAge 55 to 90 - Tests remternetug in people with an Alzheimer's-causing gene mutation
Tests remternetug against placebo in adults with a gene mutation causing early Alzheimer's.
Bron, FranceAlso Lille, Paris, Rouen, ToulouseAge 18+ - Tests remternetug in people at risk for early-onset familial Alzheimer disease
Tests remternetug against placebo in adults with a genetic mutation causing Alzheimer disease.
Bron, FranceAlso Lille, Paris, Rouen, ToulouseAge 18+ - Follows older adults with memory complaints to study early Alzheimer's signs
Yearly tests track people with memory complaints for early Alzheimer's disease changes.
Paris, FranceAge 70 to 95 - Daridorexant for Insomnia in People With Memory Problems or Early Alzheimer Disease
Tests daridorexant for insomnia in older adults with mild cognitive impairment or Alzheimer disease.
Montpellier, FranceAge 60 to 85 - Stem Cells From Donated Fat Tissue for Mild to Moderate Alzheimer Disease
Tests the safety of donor fat-derived stem cells given by vein in Alzheimer disease.
Toulouse, FranceAge 50 to 85 - Studying slowed movement and brain changes in people with Alzheimer's disease
Looks at brain scans and tests of thinking in adults with Alzheimer's disease.
Amiens, FranceAge 40 to 85
Trials that have ended are not listed here, because nobody can join them. Stopped and finished Alzheimer disease trials (research view)
Take part in research
19 official research programmes take people with this disease. In a biobank or a registry you give a blood or tissue sample, or your health data, for many research teams to use.
See the research programmesSearch the publications
The results open on the publications page in a new tab, so this page stays as it is.
Lists with this disease filtered
Where treatment stands
In the EU, lecanemab was first approved in April 2025 and donanemab in September 2025.
Approved: 12
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 29
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 5
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Lab research stage: 1
Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The EU medicines agency (EMA), ClinicalTrials.gov and the EU trials register, checked on 10 November 2026. Every treatment links to its own records; the texts are written by AI from them.
Medicines approved only in single countries are not included. We did not check in which countries a medicine is sold or paid for. Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 99 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for Alzheimer's disease. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. EU approvals newer than that data come from the European Commission’s Union Register, checked on 17 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.
Support organisations
Patient organisations and helplines in France, for you and your family.
Alzheimer disease organisations in France
- Essentiel Alzheimer – Ligne d'information 31 50
Free information line of Fondation Médéric Alzheimer's Essentiel Alzheimer platform, staffed by a specialised social worker who advises carers on administrative, medical and social questions.
- Fondation Médéric Alzheimer
Public-utility foundation: Essentiel Alzheimer carer platform, free information line 3150, guides, a directory of care structures and research funding.
- France Alzheimer et maladies apparentees
National association with 102 local associations: carer training and support groups, individual consultations, memory cafes, respite (haltes-relais), holidays, activities for people with the disease.
General support in France
- 3114 – Numéro national de prévention du suicide
France's free 24/7 national suicide prevention number, answered by trained health professionals, for people in distress and their relatives.
- S.O.S Amitié France
French volunteer listening service offering anonymous, free, caring emotional support by phone, chat and messaging, day and night.
- Santé.fr
France's official public health information service (Ministry of Health) with reliable health information and a directory of care services.
International organisations
- Alzheimer's Association
Free 24/7 Helpline (interpreters for 200+ languages), care consultations with dementia experts, local chapters, Community Resource Finder, ALZConnected online community.
- Alzheimer's Drug Discovery Foundation
Funds the early work on new Alzheimer's medicines, in universities and companies.
- BrightFocus Foundation
US nonprofit that funds research and provides public information on Alzheimer's disease, macular degeneration and glaucoma.
- Dementia Alliance International (DAI)
Organisation for people with a dementia diagnosis: free online peer support groups, webinars, Brain Health Hub, resources for care partners.
Frontlight Community
Alzheimer disease community in France
People living with Alzheimer disease and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.
You need a Frontlight account with a verified e-mail address to comment.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
12 medicines are approved for Alzheimer disease in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 4 uncertain matches are left out. Other countries' own approvals were not checked.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
See all 2About Alzheimer disease
Sources: NHS, MedlinePlus, Archives of Neurology
A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.
What is it?
Alzheimer's is the most common cause of dementia: a steady loss of memory, thinking and other mental abilities. Proteins build up in and around brain cells. One protein (amyloid) forms clumps around the cells, another (tau) forms tangles inside them. Over time parts of the brain shrink, usually the memory areas first. These changes begin many years before any signs. It is not a normal part of getting older.
Most people who get it are over 65, and the risk rises with age: about 1 in 14 people over 65 and 1 in 6 over 80 have Alzheimer's or another type of dementia. Genes usually raise the risk only a little. In a few families a single gene causes it, and then it is much more likely to be passed on.
The first signs
The signs come on slowly over several years and are sometimes taken for normal ageing.
- forget recent conversations or events;
- misplace things and forget the names of places and objects;
- struggle to find the right word, or ask the same questions again and again;
- find decisions harder and become more hesitant about trying new things;
- feel anxious, agitated or confused at times.
How doctors find out
There is no simple, reliable test. The doctor checks your general health, may order blood tests and ask about your medicines to rule out other causes, and asks you to do some memory and thinking tasks. You may then be sent to a specialist, who may work at a memory clinic, for more tests such as a brain scan (CT or MRI). Finding out can take many months and several appointments.
Current treatment
Symptom medicines (e.g. donepezil) plus support
Will it get worse?
Yes. It is a progressive illness: the symptoms get worse slowly over several years. It gets worse slowly, at a different pace for each person. In the middle stage people usually need support with everyday living, such as help with eating, washing, getting dressed and using the toilet. In the severe stages they may need full-time care. People may live for several years after the signs begin, but this varies a lot. Alzheimer's shortens life, though many people with it die of something else.
Medicines: what helps, and what to watch for
Medicines cannot cure Alzheimer's, but some can ease the symptoms for a time. Donepezil, galantamine and rivastigmine raise acetylcholine, a brain chemical that helps nerve cells pass messages; they are used in the early and middle stages. Memantine works in a different way and is used when the disease is moderate or severe.
Good to know:
- specialists, such as psychiatrists or neurologists, can prescribe these medicines; your family doctor may prescribe them on a specialist's advice;
- feeling sick, being sick and losing your appetite can be side effects, and they usually get better after about 2 weeks;
- memantine can cause headaches, dizziness and constipation, which usually pass;
- for aggression or extreme distress, other ways of coping are tried first; antipsychotic medicines have serious side effects, so they should be used at the lowest dose for the shortest time possible.
Exercise and therapy help too
Some treatments without medicines can help memory, problem solving, mood and wellbeing:
- cognitive stimulation therapy: group activities and exercises for memory and problem solving;
- cognitive rehabilitation: working with a professional, such as an occupational therapist, and a relative or friend towards a personal goal, like using a mobile phone;
- reminiscence and life story work: talking about the past with the help of photos, objects or music.
Exercise regularly, for example with a daily walk, gardening, tai chi or dancing.
Median survival
About 3 to 8 years after diagnosis, depending on age at diagnosis
Measured in: Participants of the Baltimore Longitudinal Study of Aging older than 55, followed 1985–1999
The figures behind it
Baltimore Longitudinal Study of Aging (participants older than 55, followed 1985–1999): median survival 8.3 years when Alzheimer disease was diagnosed at age 65, down to 3.4 years when it was diagnosed at age 90; no significant difference between men and women.
Sources
Written in plain words by Frontlight from these pages:
- MedlinePlus: Alzheimer's Disease
- NHS: Alzheimer's disease – Overview
- NHS: Alzheimer's disease – Causes
- NHS: Alzheimer's disease – Symptoms
- NHS: Alzheimer's disease – Diagnosis
- NHS: Alzheimer's disease – Treatment
- NHS: Living well with dementia
- Archives of Neurology: Survival following a diagnosis of Alzheimer disease